Orders from 120 EUR Free delivery from 250 EUR Ready for pickup dead drop: collect in 5 min Free parcel delivery from 250 EUR

Substances · Benzodiazepines and thienodiazepines

Pyrazolam

C16H12BrN5 CAS 39243-02-2 Analytical reference material — not for human consumption
Preferred name
Pyrazolam
IUPAC name
8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Parent CAS number (reference)
39243-02-2
Molecular formula
C16H12BrN5
Molecular weight
354.2 g/mol
InChIKey
BGRWSFIQQPVEML-UHFFFAOYSA-N
PubChem
CID 12562545
Source
PubChem
Verified synonyms & catalog abbreviations
SH-I-04 Pyridinyl-bromazolam

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

Pyrazolam

Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM Triazolobenzodiazepine
Verified PubChem & CAS Identity C16H12BrN5 · CAS 39243-02-2 · CID 12562545
Calibrated Physical Form Precision Tablets · 1 Tablet = 1 mg
≥98% Analytical Purity Verified 354.2 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Selective
GABAₐ α₅ Amnestic / Cognitive Modulation Moderate

Pyridinyl-bromotriazolobenzodiazepine exhibiting preferential functional selectivity toward alpha2 and alpha3 GABA-A subunits over hypnotic alpha1 subunits.

Biotransformation & Active Metabolites

Excreted largely unchanged renally with minimal hepatic Phase I active metabolites.

Temporal Pharmacokinetics

Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM — 1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels.

  1. Onset 15–35 min
  2. Peak Window 1–2.5 h
  3. Total Window 5–8 h
  4. Residual / Half-Life 4–10 h minimal metabolite tail

1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
0.5 mg
Cognitive & Sensory

Subtle threshold receptor activity (Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
0.5–1 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
1–2 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
2–3 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
4+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Elevated Hazard — Avoid

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Caution / Receptor Attenuation

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Structural Isomer & Sibling Comparison

1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels.

Physicochemical Stability & Storage

Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Comprehensive Analytical & Toxicological Monograph

Pyrazolam (8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; CAS 39243-02-2, PubChem CID 12562545) is a triazolobenzodiazepine reference compound (C16H12BrN5, 354.2 g/mol) classified pharmacologically as a Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM. Pyridinyl-bromotriazolobenzodiazepine exhibiting preferential functional selectivity toward alpha2 and alpha3 GABA-A subunits over hypnotic alpha1 subunits. Excreted largely unchanged renally with minimal hepatic Phase I active metabolites. In published observational and toxicological literature, threshold response is noted at 0.5 mg, light range at 0.5–1 mg, common reference range at 1–2 mg, strong intensity at 2–3 mg, and heavy/adverse territory at 4+ mg, with an onset of 15–35 min, peak window of 1–2.5 h, and total duration of 5–8 h (4–10 h minimal metabolite tail). 1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels. Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemical Architecture & Structural Profile

Pyrazolam (8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C16H12BrN5 and a molar mass of 354.2 g/mol. The parent molecule is indexed under CAS registry number 39243-02-2 and in the NCBI PubChem database as CID 12562545 (Standard InChIKey: BGRWSFIQQPVEML-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Pyrazolam is indexed within the Benzodiazepines structural group. Toxicological notes (PsychonautWiki): low toxicity, potentially lethal when mixed with depressants like alcohol or opioids. Dependence liability (PsychonautWiki): extremely physically and psychologically addictive. Documented cross-tolerance class: benzodiazepines. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations